N7778

Sigma-Aldrich

7-Nitroindazole

≥98%

Synonym(s):
7-NI
Empirical Formula (Hill Notation):
C7H5N3O2
CAS Number:
Molecular Weight:
163.13
EC Number:
MDL number:
PubChem Substance ID:
NACRES:
NA.77
Pricing and availability is not currently available.

assay

≥98%

form

powder

solubility

DMF: 50 mg/mL, clear, yellow to orange

storage temp.

−20°C

SMILES string

O-N+(=O)c1cccc2cnnHc12

InChI

1S/C7H5N3O2/c11-10(12)6-3-1-2-5-4-8-9-7(5)6/h1-4H,(H,8,9)

InChI key

PQCAUHUKTBHUSA-UHFFFAOYSA-N

Gene Information

human ... NOS1(4842), NOS2(4843), NOS2B(201288), NOS2C(645740), NOS3(4846)
rat ... Nos1(24598)

Looking for similar products? Visit Product Comparison Guide

Packaging

1, 5 g in poly bottle

Biochem/physiol Actions

Selective inhibitor of nitric oxide synthase from mouse brain.

Features and Benefits

This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.
This compound is featured on the Nitric Oxide Synthases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Legal Information

LOPAC is a registered trademark of Sigma-Aldrich Co. LLC

Pictograms

Skull and crossbonesHealth hazard

Signal Word

Danger

Hazard Statements

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

Hazard Codes

T

Risk Statement

60-40

Safety Statement

53-22-36/37/39-45

RIDADR

UN 2811 6.1 / PGIII

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Morten Hedetoft et al.
Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc, 45(3), 335-350 (2018-07-22)
Experiments have shown that hyperbaric oxygen (HBO2) therapy reduces cyanide-induced cerebral distress. The exact mechanism behind HBO2's neuroprotective effect is unknown, but has been proposed to be mediated by an increased neuronal nitric oxide (NO) bioavailability, which may compete with...
Dongmei Wang et al.
Experimental neurology, 239, 111-119 (2012-10-16)
We have previously shown that intrathecal administration of the adrenomedullin (AM) receptor antagonist AM(22-52) produces a long-lasting anti-hyperalgesia effect. This study examined the hypothesis that AM recruits other pronociceptive mediators in complete Freund's adjuvant (CFA)-induced inflammation. Injection of CFA in...
Kazuhiro Takuma et al.
European journal of pharmacology, 683(1-3), 166-173 (2012-03-28)
Long-term treatment with the dopamine precursor levodopa (l-DOPA) frequently induces dyskinesia in Parkinson's disease patients, which is a major complication of this therapy. Previous studies using animal models show that repeated administration of l-DOPA results in alterations of some signaling...
Geoffrey E Ciarlone et al.
American journal of physiology. Cell physiology, 311(6), C1014-C1026 (2016-10-14)
Central CO2-chemosensitive neurons in the caudal solitary complex (cSC) are stimulated not only by hypercapnic acidosis, but by hyperoxia as well. While a cellular mechanism for the CO2 response has yet to be isolated, previous data show that a redox-sensitive...
Anita J Turner et al.
American journal of physiology. Renal physiology, 313(4), F864-F873 (2017-07-07)
Via developmental programming, prenatal perturbations, such as exposure to glucocorticoids and maternal malnutrition alter kidney development and contribute to the development of hypertension. To examine the possibility that alterations in tubuloglomerular feedback (TGF) contribute to the development of hypertension in...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.